Monthly Or Bust: Zalbin's Chances For Approval Likely Rest On Monthly Use Data
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA indicates risk-to-benefit ratio is insufficient to approve Human Genome Sciences' next-generation interferon for biweekly dosing.